BOSTON SCIENTIFIC CORP(BSX)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
BOSTON SCIENTIFIC CORP (BSX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BSX at 77.5/100 on a 32-signal composite quality model, placing it at rank #66 of 2,961 stocks — the top 5% of the AI-ranked universe. BSX scores in the top quartile across revenue scale (92.8), balance sheet strength (82.1), profitability (80.9). Shareholder dilution risk is elevated at 46.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BOSTON SCIENTIFIC CORP reports quarterly revenue of $5.4B, net income of $905.0M, an operating margin of 21.6%. Top institutional holders of BSX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. BSX trades on the NYSE exchange and files with the SEC under CIK 885725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BSX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BOSTON SCIENTIFIC CORP directly from SEC EDGAR.
AI Quality Score
77.5/100
AI Rank
#66
Revenue
$5.4B
Net Income
$905.0M
Free Cash Flow
$1.3B
Operating Margin
21.6%
BSX key financials by period
BOSTON SCIENTIFIC CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$20.1B
—
18.0%
FY 2024
10-K
$16.7B
—
15.5%
FY 2023
10-K
$14.2B
—
16.4%
FY 2022
10-K
$12.7B
—
13.0%
FY 2021
10-K
$11.9B
—
10.1%
FY 2020
10-K
$9.9B
—
-0.8%
Institutions holding BSX
Institutional investors reporting a position in BOSTON SCIENTIFIC CORP on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-03 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 net sales rose 7.5% to $5.442B on Interventional Cardiology and Electrophysiology strength, with gross margin up to 70.7% and operating income of $1.178B.
Biggest Revenue Drivers
Cardiovascular$3,624M+8.3% YoY
Growth led by coronary therapies franchise with AGENT Drug-Coated Balloon and Electrophysiology led by Farapulse PFA System
MedSurg$1,818M+5.9% YoY
Endoscopy biliary franchise and Neuromodulation pain portfolio growth, partly offset by flat Urology
Biggest Revenue Drivers
Total revenue: $5.442B+7.5% YoY
Cardiovascular$3,624M+8.3% YoY
Growth led by coronary therapies franchise with AGENT Drug-Coated Balloon and Electrophysiology led by Farapulse PFA System
Led by Farapulse Pulsed Field Ablation System, impacted by increased competition
MedSurg$1,818M+5.9% YoY
Endoscopy biliary franchise and Neuromodulation pain portfolio growth, partly offset by flat Urology
Within MedSurg
Endoscopy$793M+7.6% YoY
Driven by biliary franchise led by AXIOS Stent and Delivery System and core GI franchise
Largest Expense Items
Selling, general and administrative expenses$1,803M+5% YoY
Primarily driven by selling expenses associated with higher net sales; 80 bps lower as a percentage of net sales
Cost of products sold$1,594M-$43M YoY
Benefited from IEEPA tariff refund and a decrease in inventory charges
Research and development expenses$554M+5% YoY
Investments across businesses to maintain a product pipeline contributing to future sales growth
Amortization expense$233M+3.4% YoY
Reflects intangibles from recent acquisitions
Margins: Gross margin rose to 70.7% from 67.7%, driven by higher-margin product mix, an $83M IEEPA tariff refund and lower inventory charges, slightly offset by unfavorable foreign currency.
Watch Items from the Filing
Pending $14.5B Penumbra acquisition drew an FTC Second Request; funding includes ~$11.0B of cash and new debt plus stock, backed by a $6.000B term loan facility.
New 2026 Restructuring Plan approved July 21, 2026: pre-tax charges of $700M-$800M, $600M-$700M in cash outlays, targeting ~$500M lower gross annual pre-tax expenses.
Securities class action and four derivative suits filed over the February 4, 2026 stock drop tied to U.S. electrophysiology growth guidance; damages unspecified.
Litigation-related net charges of $76M recorded in the quarter; legal accrual rose to $282M from $242M, and federal spinal cord stimulator cases were consolidated into an MDL.
Cardiac Rhythm Management sales fell to $585M from $590M and Urology grew just 1.1%, hurt by China volume-based procurement and sacral neuromodulation commercial disruption.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
